News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,328 Results
Type
Article (184)
Press Release (1144)
Section
Business (299)
Career Advice (1)
Deals (54)
Drug Delivery (3)
Drug Development (95)
FDA (63)
Job Trends (27)
News (508)
Policy (65)
Tag
Academia (3)
Alliances (130)
Alzheimer's disease (2)
Antibody-drug conjugate (ADC) (5)
Approvals (64)
Artificial intelligence (3)
Best Places to Work (18)
Biosimilars (49)
Breast cancer (1)
Cancer (10)
Cardiovascular disease (2)
Career advice (1)
Clinical research (82)
Collaboration (11)
COVID-19 (5)
C-suite (3)
Data (8)
Diagnostics (23)
Digital health (1)
Drug discovery (2)
Drug pricing (9)
Earnings (86)
Events (124)
Executive appointments (3)
FDA (68)
Funding (2)
GLP-1 (3)
Government (13)
Guidances (1)
Healthcare (44)
Immunology and inflammation (4)
Infectious disease (6)
Inflammatory bowel disease (1)
Inflation Reduction Act (2)
Intellectual property (2)
IPO (31)
IRA (2)
Job creations (9)
Job search strategy (1)
Layoffs (3)
Legal (15)
Lung cancer (3)
Manufacturing (13)
Medical device (40)
Medtech (40)
Mergers & acquisitions (26)
Metabolic disorders (1)
Multiple sclerosis (1)
Neuroscience (3)
NextGen: Class of 2026 (9)
Non-profit (2)
Obesity (1)
Opinion (3)
Pain (1)
Patents (3)
People (65)
Pharmacy benefit managers (2)
Phase 1 (28)
Phase 2 (34)
Phase 3 (36)
Pipeline (15)
Policy (5)
Postmarket research (3)
Preclinical (3)
Prostate cancer (1)
Radiopharmaceuticals (1)
Rare diseases (1)
Real estate (13)
Regulatory (47)
Research institute (4)
Startups (7)
Supply chain (1)
The Weekly (1)
Vaccines (2)
Weight loss (1)
Date
Last 7 days (2)
Last 30 days (9)
Last 365 days (64)
2026 (10)
2025 (61)
2024 (114)
2023 (86)
2022 (198)
2021 (148)
2020 (150)
2019 (103)
2018 (106)
2017 (78)
2016 (80)
2015 (74)
2014 (33)
2013 (24)
2012 (19)
2011 (14)
2010 (10)
Location
Asia (410)
Australia (6)
California (11)
Canada (2)
China (3)
Delaware (1)
Europe (127)
Illinois (3)
Japan (4)
Maryland (3)
Massachusetts (2)
Missouri (3)
New Jersey (4)
New York (1)
Northern California (7)
Southern California (3)
Texas (2)
United States (36)
Utah (1)
Washington D.C. (1)
Washington State (2)
Wisconsin (1)
1,328 Results for "samsung bioepis".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan
December 23, 2025
·
2 min read
Press Releases
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe
January 5, 2026
·
2 min read
Press Releases
Samsung Bioepis Releases First Quarter 2026 US Biosimilar Market Report, Providing Updates to Evolving Drug Pricing Models
January 26, 2026
·
2 min read
Press Releases
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe
December 1, 2025
·
5 min read
Press Releases
Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary
November 3, 2025
·
3 min read
Press Releases
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
October 29, 2025
·
2 min read
Press Releases
Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis’ Biosimilar to Lucentis (Ranibizumab), Gains European Approval
December 2, 2025
·
2 min read
Legal
J&J Takes Samsung Bioepis to Court Over ‘Unlawful’ Stelara Biosimilar Sublicense
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar.
February 25, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Samsung Bioepis Releases Fourth Quarter 2025 US Biosimilar Market Report Providing Annual Biosimilar Trends and Future Market Trajectory
October 23, 2025
·
3 min read
Press Releases
Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors
October 20, 2025
·
4 min read
1 of 133
Next
